SAN FRANCISCO, Dec. 06, 2021 (GLOBE NEWSWIRE) — PepperLime Health Acquisition Corporation (Nasdaq: PEPLU) (the “Company”) immediately introduced that, commencing December 9, 2021, holders of the models offered in the Company’s preliminary public providing of 15,000,000 models accomplished on October 19, 2020, and a subsequent issuance of a further 2,000,000 models accomplished on October 29, 2021 pursuant to the partial train by the underwriters of their over-allotment possibility in reference to the preliminary public providing, might elect to individually commerce the shares of Class A strange shares and redeemable warrants included in the models. Those models not separated will proceed to commerce on the Nasdaq Stock Market LLC (“Nasdaq”) beneath the image “PEPLU,” and the shares of Class A strange shares and redeemable warrants which are separated will commerce on Nasdaq beneath the symbols “PEPL” and “PEPLW,” respectively. No fractional warrants will likely be issued upon separation of the models and solely complete warrants will commerce. Holders of models might want to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s switch agent, with the intention to separate the models into shares of Class A strange shares and redeemable warrants.
The Company is a clean test firm fashioned for the objective of effecting a merger, capital inventory alternate, asset acquisition, inventory buy, reorganization or related business mixture with a number of companies.
The models have been initially supplied by the Company in an underwritten providing. Oppenheimer & Co. Inc. acted as the sole book-running supervisor in the providing. The providing was made solely by way of a prospectus. Copies of the prospectus could also be obtained from: Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 85 Broad Street, twenty sixth Floor, New York, New York 10004, phone: (212) 667-8055 or electronic mail: [email protected].
A registration assertion regarding the securities grew to become efficient on October 14, 2020 in accordance with Section 8(a) of the Securities Act of 1933, as amended. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any state or jurisdiction through which such supply, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
Forward Looking Statements
This press launch might embody “forward-looking statements” inside the that means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements aside from statements of historic truth included on this press launch are forward-looking statements. When used on this press launch, phrases comparable to “anticipate,” “believe,” “estimate,” “expect,” “intend” and related expressions, as they relate to us or our administration workforce, determine forward-looking statements. Such forward-looking statements are based mostly on the beliefs of administration, in addition to assumptions made by, and data at the moment out there to, the Company’s administration. Actual outcomes might differ materially from these contemplated by the forward-looking statements because of sure components detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or individuals appearing on our behalf are certified of their entirety by this paragraph. Forward-looking statements are topic to quite a few circumstances, a lot of that are past the management of the Company, together with these set forth in the Risk Factors part of the Company’s registration assertion and prospectus regarding the Company’s preliminary public providing filed with the SEC. The Company undertakes no obligation to replace these statements for revisions or modifications after the date of this launch, besides as required by legislation.
Investor Contact:
PepperLime Health Acquisition Corporation
www.pepperlimehealth.com
Ramzi Haidamus
(415) 263-9939
Related Images
Image 1: PepperLime Health
PepperLime Health brand
This content material was issued by way of the press launch distribution service at Newswire.com.
